Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

5.40
Delayed Data
As of Apr 28
 -0.04 / -0.74%
Today’s Change
3.05
Today|||52-Week Range
10.90
+2.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$23.1M

Company Description

Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders. Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism. It also develops Seliciclib and CYC065-Second Generation CDK Inhibitor. The company was founded by Ronald J. Berenson, David Philip Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Contact Information

Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Berkeley Heights New Jersey 07922
P:(908) 517-7330
Investor Relations:

Employees

Shareholders

Mutual fund holders4.30%
Other institutional27.66%
Individual stakeholders0.82%

Top Executives

Spiro RombotisPresident, Chief Executive Officer & Director
Paul McBarronCOO, CFO, Secretary, Director & Executive VP
David GloverChief Scientist
Susan DavisDirector-Business Development
Judy ChiaoVP-Clinical Development & Regulatory Affairs